

Haem.io

The Problem

Haematologists are currently overwhelmed. The diagnosis of blood cancers like AML and MDS requires them to manually synthesise data from multiple unstructured lab reports and compare it against ever-changing, complex international guidelines. This process is slow and laborious, taking days or weeks, is prone to variation, and represents a major bottleneck in getting patients onto the correct treatment pathway.

Our Solution: Haem.io - Intelligent Diagnostics for Precision Haematology

Haem.io is a sophisticated software platform that automates this entire diagnostic process. Our unique "human-in-the-loop" hybrid AI approach uses intelligent extraction to read and understand unstructured clinical reports, then runs the data through an expert-driven formal logic engine—not a "black box" AI—that precisely mirrors the WHO and ICC guidelines. In seconds, it delivers:

1. **A Precise, Auditable Diagnosis** of the cancer subtype.
2. **An Accurate Patient Risk Score** for prognosis.
3. **A Curated List of Suitable Clinical Trials**.

Our Moat

- **Expert-Driven Logic:** Our core logic was co-invented by our senior NHS consultant haematologist co-founders, embedding decades of real-world expertise. It's transparent and verifiable.
- **Seamless Integration:** We are format-agnostic. We can consume data from any clinical system, making integration effortless and removing barriers to adoption.
- **Unmatched Team:** We have a rare fusion of high-stakes AI engineering (FinTech, CERN), deep clinical expertise (NHS consultants), and a proven ability to execute.

Traction (Traction-First, Funding-Second Strategy)

- Self-funded, production-ready alpha version is complete.
- Actively engaging with Manchester Foundation Trust (MFT), who have begun setting up our system within their testing environment.
- Strong engagement with Key Opinion Leaders (KOLs), including successful demonstration at the national AML working group.
- Strategy: We are securing 3-5 signed Letters of Intent (3 are secure already) from NHS Trusts for formal pilots *before* raising our first round of capital.

The Ask (Seed Round)

Backed by powerful letters of support from Professor Charles Craddock (Chair, UK AML Research Network) and the haematology department at The Christie, we have confirmed top-tier clinical demand for our platform. We have also been included as a technology partner on a major £7M grant submission for a national study on relapsed AML.

We are now raising **£750k in a seed round** to execute on this momentum. The capital will be used to deliver on our committed NHS pilot studies, finalise our UKCA regulatory submission, and scale our team to meet this validated demand.